Expand TEVA Menu
TEVA MENU

TEVA Latest Press Releases

-- April 16, 2024 --

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab) Business Wire 5:43 PM
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO (deutetrabenazine) Tablets Business Wire 8:00 AM

-- April 11, 2024 --

Teva Confirms Efficacy and Safety of AJOVY (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China Business Wire 8:30 AM

-- April 9, 2024 --

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024 Business Wire 4:30 PM

-- April 6, 2024 --

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY (risperidone) Extended-Release Injectable Suspension at SIRS 2024 Business Wire 1:00 PM

-- April 4, 2024 --

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate Business Wire 8:30 AM

-- April 1, 2024 --

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-'248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement Business Wire 8:30 AM

-- February 26, 2024 --

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO in China Business Wire 7:00 AM

-- February 23, 2024 --

Alvotech and Teva Announce U.S. Approval of SIMLANDI (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira Business Wire 8:15 PM

-- February 20, 2024 --

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-'574) Antibody at the 2024 ECCO Annual Meeting Business Wire 8:30 AM

-- January 31, 2024 --

Teva Reports Growth in Fourth Quarter and Full Year 2023 Business Wire 7:00 AM
Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy Business Wire 6:00 AM

-- January 2, 2024 --

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024 Business Wire 4:30 PM

-- December 28, 2023 --

Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference Business Wire 4:30 PM

-- December 14, 2023 --

Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma Business Wire 8:30 AM

-- December 6, 2023 --

New Post Hoc Phase 3 Data Analysis Shows AJOVY (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity Business Wire 2:00 AM

-- November 30, 2023 --

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment Business Wire 8:30 AM